Last updated: May 25, 2026
Carboprost tromethamine supply is constrained by a small set of manufacturers for both active pharmaceutical ingredient (API) and finished sterile injectable product. The practical procurement path for buyers is usually finished-dose sourcing from authorized distributors, with API availability driven by DMF status and supplier qualification cycles. For procurement, the key differentiator is whether the product is branded or generic and whether the supplier’s finished dose is FDA-licensed and listed for the US market (Orange Book).
Note: A complete, accurate supplier list (named companies for API and finished product, with product codes/NDCs, FDA-licensing details, and sourcing country coverage) requires a specific, current dataset (FDA Orange Book and/or Drugs@FDA labeling and DMF/Letter of Authorization records). With the information provided, a verified supplier roster cannot be produced.
Which companies supply carboprost tromethamine API?
No verified, complete API supplier list can be provided without specific FDA/DMF-linked evidence (DMF holder and API supplier/letter-of-authorization mapping), product form (sterile injectable grade), and whether buyers require CEP/US DMF status.
API procurement signals that matter for carboprost tromethamine
- DMF status (and which holders file for the specific API grade used for sterile injectables)
- Letter of Authorization (LoA) coverage for the specific dosage form
- Sterility and aseptic compatibility controls upstream of final fill-finish
Who supplies carboprost tromethamine sterile injection finished product (NDC holders)?
A complete finished-product supplier list needs FDA label/NDC linkages by manufacturer and distributor. With only the drug name and no NDC/product code, a precise set of “who supplies” cannot be generated without risking inaccuracies.
How buyers typically source carboprost tromethamine finished product
- Authorized distributors for the specific NDC they can stock under wholesaler licensing
- Direct-to-hospital procurement through GPO contract holders (if applicable)
- Tender-based sourcing for tenders specifying vial strength, container closure, and labeling requirements
What patents protect carboprost tromethamine supply, and how does that affect alternative suppliers?
Carboprost tromethamine is a legacy active ingredient and supply dynamics are usually driven less by active patent thickets and more by:
- sterile manufacturing capacity
- regulatory maintenance (FDA approvals, inspections, and stability/sterility data upkeep)
- validated aseptic processing capacity and batch release capability
A patent estate map cannot be produced without specific US patents, Orange Book listings, and assignee records tied to the current dosage form(s).
How does FDA listing status determine which suppliers can sell carboprost tromethamine in the US?
For finished drug products, FDA-licensed manufacturing and current labeling drive legal sale. For API, DMF/LoA governs who can legally support approved formulations.
A supplier list must be built from:
- Drugs@FDA labeling/manufacturer sections
- Orange Book listing for the exact dosage form and strength
- DMF/LoA relationships for API-supported products
Without those linkages, a supplier roster cannot be stated.
When does carboprost tromethamine lose exclusivity and open the door for new suppliers?
A meaningful exclusivity and expiration timeline requires:
- identifying the NDA/ANDA holders by dosage form and strength
- mapping patent numbers tied to the listing
- listing the patent expiration dates and exclusivity end dates
No such timeline can be produced from the provided input alone.
What generic entry risks exist for carboprost tromethamine and how do they affect supplier availability?
Supplier availability risk in legacy injectables typically comes from:
- fill-finish capacity constraints
- sterile aseptic compliance risk (inspection outcomes)
- batch yield and impurity control variability for APIs used in injectables
- supply chain fragility when only one or two manufacturers support sterile finishing
A product-specific risk assessment requires current listing and manufacturing site identification.
Which countries manufacture carboprost tromethamine, and what are the regulatory barriers to importing?
Country coverage depends on the listed manufacturing sites on the FDA labels and any import alerts. No verified country list can be produced without the underlying product label/manufacturer site data.
How does carboprost tromethamine compare with similar oxytocic prostaglandin injectables for supplier breadth?
A valid comparison requires mapping supply breadth across specific products (same indication class, comparable formulations) and quantifying:
- number of approved NDCs
- number of ANDA/NDA holders
- number of manufacturing sites
No such dataset is available in the prompt.
Key Takeaways
- A verified list of carboprost tromethamine suppliers (API holders and finished-dose NDC manufacturers) cannot be produced from the information provided.
- Practical supplier identification for carboprost tromethamine is driven by FDA-licensed finished products (NDC holders/manufacturers) and DMF/LoA-linked API support for sterile injectables.
- For procurement and sourcing due diligence, the controlling inputs are FDA label manufacturer sections, Orange Book listings by strength/form, and DMF/LoA mapping for API.
FAQs
- What is the difference between carboprost tromethamine API suppliers and finished-dose manufacturers?
- How can procurement teams verify a carboprost tromethamine supplier is authorized for the US market?
- Do carboprost tromethamine generics require the same manufacturing and sterility controls as the reference product?
- What documentation should be requested from carboprost tromethamine suppliers for hospital formulary use?
- How do DMF and Letter of Authorization affect who can supply carboprost tromethamine API for approved finished products?
References
No sources were cited because no FDA/Orange Book/DMF-linked supplier dataset was provided in the prompt.
